Literature DB >> 20473646

VEGF and CD31 association in pituitary adenomas.

Carolina Cristina1, María Inés Perez-Millan, Guillermina Luque, Raúl Ariel Dulce, Gustavo Sevlever, Silvia Inés Berner, Damasia Becu-Villalobos.   

Abstract

Pituitary tumors are usually less vascularized than the normal pituitary, and the role of angiogenesis in these adenomas is contentious. Appraisal of microvascular density and expression of the potent angiogenic vascular endothelial growth factor (VEGF) by immunohistochemistry has yielded controversial results, as a broad spectrum of immunostaining can be found. We determined the protein expression of VEGF and CD31, an endothelial marker, in a series of 56 surgically removed pituitary adenomas using Western blot assay. Prolactinomas had higher VEGF protein expression compared to nonfunctioning or ACTH- and GH-secreting adenomas, while CD31 was similar in the different adenoma histotypes. VEGF and CD31 were not affected by sex, age, years of adenoma evolution, or proliferation rate (Ki67 and PCNA) for all adenoma types. Only in nonfunctioning adenomas CD31 concentration increased significantly with age. There was a positive correlation between CD31 and VEGF expression when all adenoma histotypes were considered, or when prolactinomas and nonfunctioning adenomas were evaluated separately. The positive association of VEGF and CD31 expression suggests the participation of angiogenesis in adenoma development, while epithelial cell proliferation in pituitary tumors is not directly related to VEGF or CD31 expression, and other factors, such as primary genetic alterations may be involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473646     DOI: 10.1007/s12022-010-9119-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  41 in total

1.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.

Authors:  C Cristina; G Díaz-Torga; A Baldi; A Góngora; M Rubinstein; M J Low; D Becú-Villalobos
Journal:  Endocrinology       Date:  2005-04-07       Impact factor: 4.736

3.  Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro.

Authors:  P Lohrer; J Gloddek; U Hopfner; M Losa; E Uhl; U Pagotto; G K Stalla; U Renner
Journal:  Neuroendocrinology       Date:  2001-08       Impact factor: 4.914

4.  Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome.

Authors:  A K Wong; M Alfert; D H Castrillon; Q Shen; J Holash; G D Yancopoulos; L Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

5.  Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.

Authors:  T Iuchi; N Saeki; K Osato; A Yamaura
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

6.  Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis.

Authors:  Y N Park; Y B Kim; K M Yang; C Park
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

7.  Angiogenesis in pituitary adenomas and the normal pituitary gland.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; A L Harris; J A Wass
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  Immunocytochemical Investigations on the Vascularization of Pituitary Adenomas.

Authors:  Marek Pawlikowski; Hanna Pisarek; Maria Jaranowska
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

9.  Localization of vascular endothelial growth factor in nontumorous human pituitaries.

Authors:  S Vidal; K Kovacs; S M Cohen; L Stefaneanu; R V Lloyd; B W Scheithauer
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

10.  Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; J A Wass; A L Harris
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  23 in total

1.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

2.  Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Authors:  Fatemeh Mahboobifard; Farahnaz Bidari-Zerehpoosh; Zahra Davoudi; Mahshid Panahi; Leila Dargahi; Mohammad H Pourgholami; Gieve Sharifi; Neda Izadi; Masoumeh Jorjani
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 3.  Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review.

Authors:  Michael Mcculloch; Michael Russin; Arian Nachat
Journal:  Perm J       Date:  2016-07-25

4.  Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

5.  Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence.

Authors:  Ruth Sánchez-Ortiga; Laura Sánchez-Tejada; Oscar Moreno-Perez; Pedro Riesgo; Maria Niveiro; Antonio M Picó Alfonso
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

6.  Enhanced nestin expression and small blood vessels in human pituitary adenomas.

Authors:  María Inés Perez-Millan; Silvia Inés Berner; Guillermina María Luque; Cristian De Bonis; Gustavo Sevlever; Damasia Becu-Villalobos; Carolina Cristina
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

7.  Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Authors:  Maliheh Ghadir; Mohammad E Khamseh; Mahshid Panahi-Shamsabad; Mohammad Ghorbani; Hamideh Akbari; Ali Zare Mehrjardi; Maryam Honardoost; Bahram Jafar-Mohammadi
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

8.  Lactotrophs: the new and major source for VEGF secretion and the influence of ECM on rat pituitary function in vitro.

Authors:  Joachim Alfer; Joseph Neulen; Andreas Gaumann
Journal:  Oncol Rep       Date:  2015-03-13       Impact factor: 3.906

9.  Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype.

Authors:  Shingo Takano; Hiroyoshi Akutsu; Takuma Hara; Tetsuya Yamamoto; Akira Matsumura
Journal:  Int J Endocrinol       Date:  2014-11-09       Impact factor: 3.257

Review 10.  Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.

Authors:  Carolina Cristina; Guillermina María Luque; Gianina Demarchi; Felicitas Lopez Vicchi; Lautaro Zubeldia-Brenner; Maria Ines Perez Millan; Sofia Perrone; Ana Maria Ornstein; Isabel M Lacau-Mengido; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Int J Endocrinol       Date:  2014-11-18       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.